A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

NCT00645307 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Extended Release OROS® Paliperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.